This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.A pilot study was done to develop a rhesus model of genital infection with rhesus papillomavirus (RhPV) and assess their short-term persistence in the cervices and anogenital tracts of nonhuman primates. Infectious RhPV1 virions and pseudovirions with RhPV1 genome were packaged in HPV16 capsids RhPV1HPV16. Eleven animals were prescreened for pre-existing RhPV infections by pap smear, cervical colposcopy, cervical and anogenital swabs to indicate PV-induced pathology. PCR and RT-PCR was used to detect RhPV genomes or transcripts from cell samples obtained by swab. Sera was tested by ELISA for antibodies to RhPV capsid proteins. Five RhPV1 negative females had 30mg Depo Provera administered 28 days prior to RhPV1 exposure to promote thinning of the vaginal mucosal epithelium. At that time, each animal was intravaginally and cervically challenged with RhPV1HPV16. At the time of inoculation, physical and cervical exams showed response to Depo treatment in all animals with loss of vaginal wall cornification in all animals. By two months post inoculation (p.i.), there was a normal progression with slight to mild cornification of the vaginal walls for all five animals. None, however, showed any visible cervical lesions. Slightly enlarged lymph nodes were noted in one of the five animals, and increased WBC at 3 months p.i. was observed in 2 of 5 animals. PAP analysis was normal for all five animals at baseline, one and two months p.i. At month four p.i., one animal demonstrated atypical squamous cells of unknown significance/low grade SIL (ASC-US/ LGSIL) and three animals showed extensive hyperkeratosis, a significant change from the baseline results. Pathology is currently performing a more extensive follow-up assessment. A final 6 month p.i. examination and sampling timepoint will occur in January, 2008. This time point will allow us to evaluate if a progression in pathology has occurred in the papilloma virus inoculated animals.
Showing the most recent 10 out of 352 publications